Dr. Christopher Cannon is a distinguished cardiologist and internationally recognized leader in cardiovascular medicine and clinical research. He currently serves as Professor of Medicine at Harvard Medical School and Senior Physician in the Cardiovascular Division at Brigham and Women's Hospital in Boston. After earning his MD from Columbia University College of Physicians and Surgeons in 1986, he completed his internal medicine residency at Columbia Presbyterian Medical Center followed by a cardiovascular fellowship at Brigham and Women's Hospital. Dr. Cannon has dedicated his career to advancing cardiovascular care through rigorous clinical research, serving as a principal investigator for over twenty multicenter clinical trials that have shaped modern treatment paradigms for heart disease. His leadership extends to his role as Director of Education in Brigham's Cardiovascular Innovation group and his twenty-five year tenure as an investigator in the TIMI Study Group.
Dr. Cannon's groundbreaking research has fundamentally transformed the understanding and management of acute coronary syndromes, atrial fibrillation, and cardiometabolic conditions through his leadership of landmark clinical trials including TACTICS-TIMI 18, PROVE IT, IMPROVE IT, and RE-DUAL PCI. His work has established evidence-based treatment protocols that have been incorporated into international clinical guidelines, directly improving patient outcomes for millions suffering from cardiovascular disease worldwide. With over one thousand original publications, reviews, and book chapters to his name, Dr. Cannon has systematically advanced the fields of lipid management, diabetes in cardiovascular disease, and prevention strategies through meticulous clinical investigation. His current leadership of the EVOLVE-MI trial continues his tradition of addressing critical unanswered questions in cardiovascular medicine with methodological rigor and clinical relevance.
Beyond his research contributions, Dr. Cannon has significantly shaped cardiovascular medicine as Editor-in-Chief of the Harvard Heart Letter and through numerous leadership roles with professional organizations including the American College of Cardiology and American Heart Association. He has received prestigious recognition including the 2024 Gold Medal Award for Outstanding Achievements in Medical Research from Columbia University's VP&S Alumni Association and leadership awards from major cardiovascular societies. As Executive Director of Cardiometabolic initiatives at Brigham and Women's Hospital, Dr. Cannon continues to mentor the next generation of cardiovascular researchers while advancing innovative approaches to integrated cardiometabolic care. His ongoing work focuses on optimizing anticoagulation strategies, refining lipid-lowering therapies, and developing comprehensive approaches to prevent cardiovascular events in high-risk populations, ensuring his continued impact on the future of cardiovascular medicine.
